Journal of Hepatology
Volume 33, Issue 3 , Pages 407-414 , September 2000

Induction of type 1 plasminogen activator inhibitor in human liver ischemia and reperfusion

Received 23 August 1999 ,Revised 3 January 2000 ,Accepted 28 February 2000.

References 

  1. Loskutoff DJ, Ny T, Sawdey M, Lawrence D. Fibrinolytic system of cultured endothelial cells: regulation by plasminogen activator inhibitor. J Cell Biochem. 1986;32:273–280
  2. Hanss M, Collen D. Secretion of tissue-type plasminogen activator and plasminogen activator inhibitor by cultured human endothelial cells: modulation by thrombin, endotoxin, and histamine. J Lab Clin Med. 1987;109:97–104
  3. Schleef RR, Higgins DL, Pillemer E, Levitt LJ. Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor. J Clin Invest. 1989;83:1747–1752
  4. Laiho M, Saksela O, Andreasen PA, Keski-Oja J. Enhanced production and extracellular deposition of the endothelial-type plasminogen activator inhibitor in cultured human lung fibroblasts by transforming growth factor-beta. J Cell Biol. 1986;103:2403–2410
  5. Mimuro J, Schleef RR, Loskutoff DJ. Extracellular matrix of cultured bovine aortic endothelial cells contains functionally active type 1 plasminogen activator inhibitor. Blood. 1987;70:721–728
  6. Cubellis MV, Andreasen P, Ragno P, Mayer M, Dano K, Blasi F. Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor. Proc Natl Acad Sci U S A. 1989;86:4828–4832
  7. Ellis V, Wun TC, Behrendt N, Ronne E, Dano K. Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors. J Biol Chem. 1990;265:9904–9908
  8. Sprengers ED, Princen HM, Kooistra T, van Hinsbergh VW. Inhibition of plasminogen activators by conditioned medium of human hepatocytes and hepatoma cell line Hep G2. J Lab Clin Med. 1985;105:751–758
  9. Schneiderman J, Sawdey M, Craig H, Thinnes T, Bordin G, Loskutoff DJ. Type 1 plasminogen activator inhibitor gene expression following partial hepatectomy. Am J Pathol. 1993;143:753–762
  10. Thornton AJ, Bruzdzinski CJ, Raper SE, Gelehrter TD. Plasminogen activator inhibitor-1 is an immediate early response gene in regenerating rat liver. Cancer Res. 1994;54:1337–1343
  11. Podor TJ, Hirsh J, Gelehrter TD, Zeheb R, Torry D, Guigoz Y, et al.  Type 1 plasminogen activator inhibitor is not an acute phase reactant in rats. Lack of IL-6- and hepatocyte-dependent synthesis. J Immunol. 1993;150:225–235
  12. Shimada M, Matsumata T, Yamamoto K, Itasaka H, Taketomi A, Sugimachi K. Initiation of a fibrinolytic system in hepatic resection: the roles of tissue-type plasminogen activator and plasminogen activator inhibitor-1. Surg Today. 1994;24:780–784
  13. Tsuji K, Eguchi Y, Kodama M. Postoperative hypercoagulable state followed by hyperfibrinolysis related to wound healing after hepatic resection. J Am Coll Surg. 1996;183:230–238
  14. Pringle JH. Notes on the arrest of hepatic hemorrhage due to trauma. Ann Surg. 1908;48:541–549
  15. Sugawara Y, Kubota K, Ogura T, Esumi H, Inoue K, Takayama T, et al.  Increased nitric oxide production in the liver in the perioperative period of partial hepatectomy with Pringle's maneuver. J Hepatol. 1998;28:212–220
  16. Leebeek FW, Kluft C, Knot EA, de Maat MP, Wilson JH. A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis. Gastroenterology. 1991;101:1382–1390
  17. Makuuchi M, Hasegawa H, Yamazaki S. Ultrasonically guided subsegmentectomy. Surg Gynecol Obstet. 1985;161:346–350
  18. Nielsen NC. Spectrophotometric determination of ICG in plasma especially with a view to an improved correction for blank density. Scand J Clin Lab Invest. 1963;15:613–621
  19. Sugawara Y, Kubota K, Ogura T, Esumi H, Inoue K, Takayama T, et al.  Protective effect of prostaglandin E1 against ischemia/reperfusion-induced liver injury: results of a prospective, randomized study in cirrhotic patients undergoing subsegmentectomy. J Hepatol. 1998;29:969–976
  20. Sugawara Y, Sakata Y, Minowada S, Hamada H, Yoshida Y, Sato O, et al.  Adenovirus-mediated transfer of tissue-type plasminogen activator gene to human endothelial cells. Surgery. 1997;122:91–100
  21. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156–159
  22. Sugawara Y, Mizugaki Y, Uchida T, Torii T, Imai S, Makuuchi M, et al.  Detection of Epstein-Barr virus (EBV) in hepatocellular carcinoma tissue: a novel EBV latency characterized by the absence of EBV-encoded small RNA expression. Virology. 1999;256:196–202
  23. Peterson GL. A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal Biochem. 1977;83:346–356
  24. Bakker CM, Metselaar HJ, Groenland TN, Gomes MJ, Knot EA, Hesselink EJ, et al.  Increased tissue-type plasminogen activator activity in orthotopic but not heterotopic liver transplantation: the role of the anhepatic period. Hepatology. 1992;16:404–408
  25. Dzik WH, Arkin CF, Jenkins RL, Stump DC. Fibrinolysis during liver transplantation in humans: role of tissue-type plasminogen activator. Blood. 1988;71:1090–1095
  26. de Boer JP, Abbink JJ, Brouwer MC, Meijer C, Roem D, Voorn GP, et al.  PAI-1 synthesis in the human hepatoma cell line HepG2 is increased by cytokines - evidence that the liver contributes to acute phase behaviour of PAI-1. Thromb Haemost. 1991;65:181–185
  27. Medina R, Socher SH, Han JH, Friedman PA. Interleukin-1, endotoxin or tumor necrosis factor/cachectin enhance the level of plasminogen activator inhibitor messenger RNA in bovine aortic endothelial cells. Thromb Res. 1989;54:41–52
  28. Emeis JJ, Kooistra T. Interleukin 1 and lipopolysaccharide induce an inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells. J Exp Med. 1986;163:1260–1266
  29. Nachman RL, Hajjar KA, Silverstein RL, Dinarello CA. Interleukin 1 induces endothelial cell synthesis of plasminogen activator inhibitor. J Exp Med. 1986;163:1595–1600
  30. van Hinsbergh VW, Kooistra T, van den Berg EA, Princen HM, Fiers W, Emeis JJ. Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo. Blood. 1988;72:1467–1473
  31. Clavien PA, Camargo CA, Gorczynski R, Washington MK, Levy GA, Langer B, et al.  Acute reactant cytokines and neutrophil adhesion after warm ischemia in cirrhotic and noncirrhotic human livers. Hepatology. 1996;23:1456–1463
  32. Fujii S, Sobel BE. Induction of plasminogen activator inhibitor by products released from platelets. Circulation. 1990;82:1485–1493
  33. Rieder H, Armbrust T, Meyer zum Büschenfelde KH, Ramadori G. Contribution of sinusoidal endothelial liver cells to liver fibrosis: expression of transforming growth factor-beta 1 receptors and modulation of plasmin-generating enzymes by transforming growth factor-beta 1. Hepatology. 1993;18:937–944
  34. Busso N, Nicodeme E, Chesne C, Guillouzo A, Belin D, Hyafil F. Urokinase and type I plasminogen activator inhibitor production by normal human hepatocytes: modulation by inflammatory agents. Hepatology. 1994;20:186–190
  35. Hopkins WE, Fujii S, Sobel BE. Synergistic induction of plasminogen activator inhibitor type-1 in HEP G2 cells by thrombin and transforming growth factor-beta. Blood. 1992;79:75–81
  36. Knittel T, Fellmer P, Ramadori G. Gene expression and regulation of plasminogen activator inhibitor type I in hepatic stellate cells of rat liver. Gastroenterology. 1996;111:745–754
  37. Sawdey M, Podor TJ, Loskutoff DJ. Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells. Induction by transforming growth factorbeta, lipopolysaccharide, and tumor necrosis factor-alpha. J Biol Chem. 1989;264:10396–10401
  38. Harvey PRC, Iu S, McKeown CMB, Petrunka CN, Ilson RG, Strasberg SM. Adenine nucleotide tissue concentrations and liver allograft viability after cold preservation and warm ischemia. Transplantation. 1988;45:1016–1020
  39. Hill SA, Shaughnessy SG, Joshua P, Ribau J, Austin RC, Podor TJ. Differential mechanisms targeting type 1 plasminogen activator inhibitor and vitronectin into the storage granules of a human megakaryocytic cell line. Blood. 1996;87:5061–5073
  40. De Petro G, Tavian D, Copeta A, Portolani N, Giulini SM, Barlati S. Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma. Cancer Res. 1998;58:2234–2239
  41. Roulot D, Sevcsik AM, Coste T, Strosberg AD, Marullo S. Role of transforming growth factor beta type II receptor in hepatic fibrosis: studies of human chronic hepatitis C and experimental fibrosis in rats. Hepatology. 1999;29:1730–1738
  42. Bensi G, Raugei G, Palla E, Carinci V, Tornese Buonamassa D, Melli M. Human interleukin-1 beta gene. Gene. 1987;52:95–101
  43. Wang AM, Creasey AA, Ladner MB, Lin LS, Strickler J, Van Arsdell JN, et al.  Molecular cloning of the complementary DNA for human tumor necrosis factor. Science. 1985;228:149–154
  44. Ponte P, Ng SY, Engel J, Gunning P, Kedes L. Evolutionary conservation in the untranslated regions of actin mRNAs: DNA sequence of a human beta-actin cDNA. Nucleic Acids Res. 1984;12:1687–1696

PII: S0168-8278(00)80276-7

Journal of Hepatology
Volume 33, Issue 3 , Pages 407-414 , September 2000

Article Tools

* Image Usage & Resolution